Benitec Biopharma Inc. (BNTC) News

Benitec Biopharma Inc. (BNTC): $10.92

0.41 (+3.90%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add BNTC to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#86 of 328

in industry

Filter BNTC News Items

BNTC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest BNTC News From Around the Web

Below are the latest news stories about BENITEC BIOPHARMA INC that investors may wish to consider to help them evaluate BNTC as an investment opportunity.

Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

Announcement marks the initiation of the first clinical trial conducted in human subjects employing Benitec’s “Silence and Replace” DNA-directed RNA interference gene therapy platformHAYWARD, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, tod

Yahoo | November 30, 2023

Here's Why Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Compensation Is The Least Of Shareholders Concerns

Key Insights Benitec Biopharma will host its Annual General Meeting on 6th of December Total pay for CEO Jerel Banks...

Yahoo | November 30, 2023

Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference

HAYWARD, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec, will participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference on Thursday,

Yahoo | November 17, 2023

Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update

19 subjects enrolled in the OPMD Natural History Study, with multiple subjects entering the eligibility period this year for entry into the BB-301 Phase 1b/2a Clinical Treatment StudyHAYWARD, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced financial res

Yahoo | November 13, 2023

Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update

Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related Dysphagia 15 subjects enrolled in the OPMD Natural History Study, with multiple subjects entering the eligibility period this year for entry into the BB-301 Phase 1b/2a Clinical Treatment Study Successful Closing of a $30.9 M Public Offering HAYWARD, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or

Yahoo | September 21, 2023

Citadel Advisors LLC Acquires New Stake in Benitec Biopharma Inc

On August 11, 2023, Citadel Advisors LLC, a renowned investment firm, made a significant move in the stock market by acquiring a new stake in Benitec Biopharma Inc. This article provides an in-depth analysis of this transaction, the profiles of both Citadel Advisors LLC and Benitec Biopharma Inc, and the potential implications for value investors. Citadel Advisors LLC purchased 173,880 shares of Benitec Biopharma Inc at a price of $2.81 per share. This transaction marked a new holding for the firm, increasing their total shares in Benitec Biopharma Inc to 173,880.

Yahoo | August 22, 2023

JANUS HENDERSON GROUP PLC Acquires New Stake in Benitec Biopharma Inc

On August 9, 2023, JANUS HENDERSON GROUP PLC, a London-based investment firm, made a significant move in the biotechnology sector by acquiring 206,170 shares of Benitec Biopharma Inc (NASDAQ:BNTC). Despite the substantial share acquisition, the impact on the firm's portfolio was not significant, with the position in BNTC representing 0% of the total portfolio. The firm now holds 9.90% of Benitec Biopharma Inc's total shares.

Yahoo | August 19, 2023

Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering

HAYWARD, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") “Silence and Replace” platform, today announced it closed its previously announced underwritten public offering of 15,544,041 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof)

Yahoo | August 11, 2023

Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering

HAYWARD, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") “Silence and Replace” platform, today announced the pricing of its underwritten public offering of 15,544,041 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanyin

Yahoo | August 9, 2023

Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023

HAYWARD, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) “Silence and Replace” platform, announced today that it will effect a 1-for-17 reverse stock split (“Reverse Stock Split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective on Ju

Yahoo | July 25, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!